Protagonist Therapeutics Inc. (PTGX)
NASDAQ: PTGXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
Pre-market: 140.25 -0.48%
PTGX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $9.12B
- P/E (TTM)
- 136.82
- EPS (TTM)
- $1.03
- Dividend yield
- None
- 52-week range
- 65.56 – 160.81
- Day range
- 137.25 – 144.10
- Volume / Avg
- 927.27K / 632.64K
- Beta
- —
- Shares outstanding
- 64.71M
- Next earnings
- Nov 5, 2026
52-week range
PTGX stock today
On Oct 7, PTGX ended the session at $140.92, adding $2.23 (1.61%), versus the S&P 500's 0.22% decline. Shares are 12.4% below their 52-week high of $160.81, set on Aug 19, 2026 and 114.9% above the 52-week low of $65.56, in the middle of the past year's range. PTGX is up 61.3% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 115.2%.
Protagonist Therapeutics trades at 136.8x its trailing twelve-month earnings per share of $1.03. Protagonist Therapeutics's next earnings report is expected on Nov 5, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Protagonist Therapeutics
Company profileProtagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Dinesh V. Patel Ph.D.
- Headquarters
- Newark, CA
- Employees
- 141
- IPO year
- 2016
- Website
- protagonist-inc.com
Financial highlights
Full financialsIn fiscal 2025, Protagonist Therapeutics generated $46.0 million in revenue, down 89.4% from fiscal 2024, its first annual decline since 2022. Protagonist Therapeutics reported a net loss of $130.1 million, compared with net income of $275.2 million a year earlier. Operating margin was -343.6%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $46.02M | $434.43M | $60.00M | $26.58M | $27.36M |
| Growth | -89.41% | +624.05% | +125.73% | -2.84% | -4.44% |
| Net income | $-130.15M | $275.19M | $-78.95M | $-127.39M | $-125.55M |
| EPS (diluted) | $-2.05 | $4.23 | $-1.39 | $-2.60 | $-2.71 |
Analyst forecast
ForecastConsensus (13 analysts)
strong_buy
Avg. price target
$174.69+23.96%
- Strong buy 3
- Buy 10
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 5, 2026
- EPS estimate
- $2.19
- Last reported (Q2 2026)
- Aug 5, 2026
- EPS actual vs est.
- $2.29 vs —
PTGX news
All PTGX newsProtagonist Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| AXSMAxsome Therapeutics Inc. | 172.97 | -0.79% | $9.06B | vs PTGX |
| ARWRArrowhead Pharmaceuticals Inc. | 61.48 | -0.10% | $8.68B | vs PTGX |
| CYTKCytokinetics Incorporated | 61.12 | -0.37% | $8.50B | vs PTGX |
| TGTXTG Therapeutics Inc. | 52.95 | +1.46% | $8.11B | vs PTGX |
| PRAXPraxis Precision Medicines Inc. | 278.02 | -0.76% | $7.76B | vs PTGX |
| RDYDr. Reddy's Laboratories Ltd | 12.27 | -1.76% | $10.22B | vs PTGX |
| ABVXAbivax SA ADR | 87.01 | -1.37% | $7.59B | vs PTGX |
| SYRESpyre Therapeutics Inc. | 80.85 | +0.92% | $7.46B | vs PTGX |
Indexes, lists and sector
Protagonist Therapeutics stock FAQ
What is Protagonist Therapeutics's stock price today?
PTGX last traded at $140.92 as of Oct 7, 4:00 PM EDT, up 1.61% on the day. Prices are delayed at least 15 minutes.
When is Protagonist Therapeutics's next earnings date?
Protagonist Therapeutics is expected to report earnings on Thursday, November 5, 2026. Analysts expect EPS of $2.19.
What is PTGX's P/E ratio?
PTGX trades at a trailing P/E ratio of 136.82.
Who is Protagonist Therapeutics's CEO?
Dr. Dinesh V. Patel Ph.D. is the chief executive officer of Protagonist Therapeutics Inc., which has about 141 employees.
What is the PTGX 52-week high?
The 52-week high for PTGX is $160.81 and the 52-week low is $65.56. The stock is currently 12.4% below its high.